title: Basiliximab induction therapy in kidney transplantation: benefits for long term allograft function after 10 years?
abstract: The interleukin-2 receptor antagonist basiliximab has proven in large clinical trials to be safe and effective to reduce acute rejections in the first year after renal transplantation. Since acute rejections are a risk factor for chronic graft loss, their effective reduction might have a positive effect on long term allograft survival. So far data is spares to prove this hypothesis and 10-year follow up on basiliximab induction therapy is not available. In our center, 41 patients were enrolled in the multicenter trial CHIB201 in 1995/96 comparing basiliximab vs no induction therapy after renal transplantation. We retrospectively analyzed the outcome of these patients after 10 years. The main reason for patient death with functioning graft were infectious complications (basiliximab: 3/20, placebo 1/19), 21% of all patients developed cancer without an obvious correlation to specific immunosuppression. Death censored 10-year graft survival was equivalent in both groups: 65% in the basiliximab and 68% in the placebo group with a mean s-creatinine-clearance of 60 and 44 ml/min. In this small study patient and graft survival was equivalent 10 years after transplantation comparing basiliximab induction therapy and placebo.
authors.affiliation: Klinik fuer Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, Germany. martina.koch@uke.uni.hamburg.de
authors.forename: Martina
authors.initials: M
authors.lastname: Koch
authors.forename: Thomas
authors.initials: T
authors.lastname: Becker
authors.forename: Rainer
authors.initials: R
authors.lastname: Lueck
authors.forename: Michael
authors.initials: M
authors.lastname: Neipp
authors.forename: Juergen
authors.initials: J
authors.lastname: Klempnauer
authors.forename: Bjoern
authors.initials: B
authors.lastname: Nashan
references.citation: Transplantation. 2004 Jan 27;77(2):166-76
references.pmid: 14742976
references.citation: Transplantation. 1994 Mar 27;57(6):857-9
references.pmid: 8154032
references.citation: Transplant Proc. 1993 Feb;25(1 Pt 2):901-2
references.pmid: 8442261
references.citation: Transpl Int. 2006 Jun;19(6):446-57
references.pmid: 16771865
references.citation: Lancet. 1997 Oct 25;350(9086):1193-8
references.pmid: 9652559
references.citation: Transpl Int. 2006 Nov;19(11):908-14
references.pmid: 17018126
references.citation: Clin Transplant. 1994 Jun;8(3 Pt 2):328-31
references.pmid: 8061375
references.citation: Transplantation. 1995 Oct 15;60(7):748-56
references.pmid: 7570988
references.citation: Am J Transplant. 2004 Jun;4(6):905-13
references.pmid: 15147424
references.citation: Exp Clin Transplant. 2004 Jun;2(1):201-7
references.pmid: 15859929
references.citation: Am J Transplant. 2004 Jun;4(6):841-2
references.pmid: 15147414
references.citation: Nephron. 1976;16(1):31-41
references.pmid: 1244564
references.citation: Transplant Proc. 1999 Feb-Mar;31(1-2):1271-2
references.pmid: 10083567
references.citation: N Engl J Med. 1990 Dec 20;323(25):1723-8
references.pmid: 2100991
references.citation: Transplantation. 2007 Jul 15;84(1):75-82
references.pmid: 17627241
references.citation: Transpl Int. 2006 Oct;19(10):814-20
references.pmid: 16961773
references.citation: Transplantation. 1999 Jan 27;67(2):276-84
references.pmid: 10075594